The pharmaceutical giant, on Tuesday, said it will begin testing of the experimental vaccine in the US next week.
This is coming a week after Germany approved human trial of a possible COVID-19 vaccine. The vaccine, named BNT162, was developed by Biontech, a Mainz-based company.
The company had said the vaccine would be tested in the US after the human trials in Germany.
READ ALSO: US govt analysis fingers Wuhan laboratory as source of COVID-19
The United Kingdom had also announced that there would be clinical trials of a potential COVID-19 vaccine.
The World Health Organisation (WHO) said there are about 20 different potential COVID-19 vaccines currently in development.
Some of the companies working on a vaccine said they are accelerating the timeline for testing as experts predict that the COVID-19 pandemic may last till 2021.
According to Worldometer, confirmed cases of COVID-19 globally have risen to 3,150,478, with 218,466 deaths. But 964,161 persons have recovered.
READ ALSO: EXPLAINER: Not a loan, no conditionalities… What to know about IMF’s $3.4bn to Nigeria
Are you an artiste? Do you want your music to go viral and reach a large number of audience? Promote your music and Submit your story on Ujuayalogusblog.com by clicking here. For Advert Inquiries Tel/+44(0)7590363984
For More: Subscribe to Ujuayalogusblog.com
No comments:
Post a Comment